Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
In the latest session, Bristol-Myers Squibb Co (NYSE: BMY) closed at $43.41 down -1.70% from its previous closing price of $44.16. In other words, the price has decreased by -$1.70 from its previous closing price. On the day, 21.33 million shares were traded. BMY stock price reached its highest trading level at $44.46 during the session, while it also had its lowest trading level at $43.19.
Ratios:
For a deeper understanding of Bristol-Myers Squibb Co’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.49 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.06. For the most recent quarter (mrq), Quick Ratio is recorded 1.11 and its Current Ratio is at 1.21. In the meantime, Its Debt-to-Equity ratio is 2.92 whereas as Long-Term Debt/Eq ratio is at 2.64.
On April 22, 2025, Cantor Fitzgerald started tracking the stock assigning a Neutral rating and target price of $55.Cantor Fitzgerald initiated its Neutral rating on April 22, 2025, with a $55 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 02 ’25 when Elkins David V sold 56,000 shares for $47.33 per share. The transaction valued at 2,650,480 led to the insider holds 167,379 shares of the business.
Elkins David V bought 56,000 shares of BMY for $2,648,800 on Sep 02 ’25. On Aug 02 ’25, another insider, Short Bartie Wendy, who serves as the EVP, Corporate Affairs of the company, sold 378 shares for $44.23 each. As a result, the insider received 16,719 and left with 5,066 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMY now has a Market Capitalization of 88358264832 and an Enterprise Value of 125798268928. As of this moment, Bristol-Myers’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.52, and their Forward P/E ratio for the next fiscal year is 7.20. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.24. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.85 while its Price-to-Book (P/B) ratio in mrq is 5.07. Its current Enterprise Value per Revenue stands at 2.637 whereas that against EBITDA is 6.581.
Stock Price History:
The Beta on a monthly basis for BMY is 0.34, which has changed by -0.14731878 over the last 52 weeks, in comparison to a change of 0.15101504 over the same period for the S&P500. Over the past 52 weeks, BMY has reached a high of $63.33, while it has fallen to a 52-week low of $42.96. The 50-Day Moving Average of the stock is -7.09%, while the 200-Day Moving Average is calculated to be -16.27%.
Shares Statistics:
For the past three months, BMY has traded an average of 12.31M shares per day and 16090400 over the past ten days. A total of 2.04B shares are outstanding, with a floating share count of 2.03B. Insiders hold about 0.06% of the company’s shares, while institutions hold 82.19% stake in the company. Shares short for BMY as of 1756425600 were 31193823 with a Short Ratio of 2.39, compared to 1753920000 on 30920136. Therefore, it implies a Short% of Shares Outstanding of 31193823 and a Short% of Float of 1.53.
Dividends & Splits
According to the company, the forward annual dividend rate for BMY is 2.46, from 2.46 in the trailing year. Against a Trailing Annual Dividend Yield of 0.055706523. The stock’s 5-year Average Dividend Yield is 3.71.
Earnings Estimates
Bristol-Myers Squibb Co (BMY) is currently under the scrutiny of 20.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $1.58, with high estimates of $1.73 and low estimates of $1.33.
Analysts are recommending an EPS of between $6.64 and $6.26 for the fiscal current year, implying an average EPS of $6.52. EPS for the following year is $6.02, with 26.0 analysts recommending between $6.83 and $4.94.
Revenue Estimates
A total of 18 analysts believe the company’s revenue will be $11.75B this quarter.It ranges from a high estimate of $12.06B to a low estimate of $11.48B. As of the current estimate, Bristol-Myers Squibb Co’s year-ago sales were $11.89BFor the next quarter, 18 analysts are estimating revenue of $12B. There is a high estimate of $12.26B for the next quarter, whereas the lowest estimate is $11.69B.
A total of 25 analysts have provided revenue estimates for BMY’s current fiscal year. The highest revenue estimate was $47.83B, while the lowest revenue estimate was $46.1B, resulting in an average revenue estimate of $47.26B. In the same quarter a year ago, actual revenue was $48.3BBased on 25 analysts’ estimates, the company’s revenue will be $43.45B in the next fiscal year. The high estimate is $45.49B and the low estimate is $41.43B.
